{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"1.4","value":"0.8"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"2.1","value":"1.1"},{"groupId":"OG002","lowerLimit":"0.7","upperLimit":"0.9","value":"0.7"},{"groupId":"OG003","lowerLimit":"0.7","upperLimit":"2.2","value":"0.8"},{"comment":"The upper limit of the 95% confidence interval was not estimable at the time of the final analysis due to an insufficient number of participants with events within the length of follow-up in assessing the number of events","groupId":"OG004","lowerLimit":"0.8","upperLimit":"NA","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better), according to the 2016 IMWG response criteria. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\<200 mg/24 h.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose on Day 1 of every 3 weeks (Q3W) as a 30-60 minute intravenous (IV) infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG000","title":"Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q3W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG001","title":"Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every 6 weeks (Q6W) as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG002","title":"Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG003","title":"Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death. For this arm, dose modification decisions were determined by the results of the Ocular Surface Disease Index (OSDI) questionnaire or VA assessments using Snellen chart. The OSDI scale assesses the severity of eye symptoms and their impact and Snellen chart is for the assessment of visual acuity.","id":"OG004","title":"Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat Population. Only those participants with confirmed partial response (PR) or better (i.e., PR, VGPR, CR and sCR) have been analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 152 weeks","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Months"}